Only 65% of those aged 15 to 24 at high risk of HIV accessed the treatment in 2024, compared with 81% of people aged 50 to 64.

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation Interventional procedure consultation Interventional procedures guidance 28 October 2025 ...

All NICE products on oesophageal cancer. Includes any guidance and quality standards.